A pegylated formulation containing DFP-10917, an analogue of the nucleoside deoxycytidine, with potential antineoplastic activity. Upon administration, the pegylated deoxycytidine analogue DFP-14927 is incorporated into the DNA of rapidly proliferating cells, such as tumor cells, and directly inhibits the activity of DNA polymerase, which results in the inhibition of DNA replication and cell cycle arrest, DNA fragmentation, and tumor cell apoptosis.